FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-028									
Estimated average burden									
hours por rosponso:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Borges Luis					2. Issuer Name and Ticker or Trading Symbol Century Therapeutics, Inc. [IPSC]							ck all applica Director			10% Ov	/ner		
(Last) 3675 MA	(F ARKET STI	,	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 02/02/2023)	below)		Other (s below) entific Officer		pecity		
(Street) PHILAD (City)	ELPHIA P		19104 (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
		Та	ble I - Non	-Derivat	ive S	ecuritie	s Acq	quired, l	Disp	osed o	of, or E	ene	ficially	Owned				
Date				2. Transac Date (Month/Da	Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acqui					5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code	v	Amount	Amount (A) or (D)		Price	Transaction(s) (Instr. 3 and 4)				(
Common Stock ⁽¹⁾ 02/0				02/02/2	2/2023		Α		21,87	75	A	\$0	21,875			D		
Common Stock ⁽¹⁾ 02/02				02/02/2	2/2023		Α		21,875		A	\$0	43,750			D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Yo	Code	saction (Instr.	Derivative E		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title of Secu Underly Derivat (Instr. 3	rities ing ve Se	curity	8. Price of Derivative Security (Instr. 5)		re es ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)		Date Exercisabl		xpiration ate	Title	OI N	mount r umber f Shares		(Instr. 4)	ion(s)		
Stock Option	\$4.6A	02/02/2023				131 250		(2)		2/02/2033	Commo	n 1	31 250	\$0	131.2	50	D	

Explanation of Responses:

(right to buy) Stock Option (right to

buy)

\$4.64

\$4.64

1. Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutic, Inc.'s (the "Company's") common stock. The RSUs vest 25% on February 2, 2024 and the remaining 75% vest on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock.

(2)

02/02/2033

02/02/2033

Commor Stock

131,250

131,250

/s/ Michael Diem, Attorney-in-02/06/2023 Fact

131,250

131,250

\$<mark>0</mark>

\$0

131,250

131,250

D

D

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

02/02/2023

02/02/2023

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{2.} The option vests 25% on February 2, 2024, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer.